Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

e amount of 0.0032% or less of Bcr-Abl compared to Gleevec (32% taking Tasigna 300 mg twice daily and 15% taking Gleevec 400 mg once daily). The ENESTnd study also continued to show that first-line treatment with Tasigna resulted in significantly fewer patients progressing to advanced phase and blast crisis (AP/BC) stages of disease compared to Gleevec, leading to a significantly lower number of CML-related deaths in patients taking Tasigna versus Gleevec (p=0.0356)(2).

"Data from both ENESTnd and ENESTcmr reinforce that patients taking Tasigna have a greater chance of achieving CMR, the deepest level of response measurable today, compared to those taking Gleevec," said Timothy P. Hughes, MD, ENEST study investigator and Clinical Professor at the University of Adelaide, Australia. "We are encouraged by what we saw in ENESTcmr and further follow-up on both trials should help to determine if more patients can reach undetectable levels of CML over time, which could have important implications for determining criteria for future studies on discontinuation of therapy."

CML is a disease in which the body produces cancerous white blood cells. Almost all patients with CML have an abnormality known as the Philadelphia chromosome, which is comprised of a protein called Bcr-Abl that causes malignant white blood cells to proliferate(3). The success of treatment for CML can be measured by a test called real-time quantitative polymerase chain reaction (RQ-PCR). A molecular response means RQ-PCR shows a reduction in Bcr-Abl in the blood; a CMR means no Bcr-Abl is detected(4,5).

"Data from the ENESTnd 36-month update and the ENESTcmr trial at ASH continue to reinforce the benefits of Tasigna over Gleevec, and support the use of Tasigna for adult patients with chronic-phase Ph+ CML," said Herve Hoppenot, President, Novartis Oncology. "We look forward to even more progress in the future as we observe the impact of achieving deep and sustained molecula
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), today ... of the study presented by a prominent heart ... and concurrently published by the Journal of ... in patients with moderate to severe chronic heart ... the heart,s ability to pump blood, and reduces ...
(Date:9/2/2014)... , Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood instrumentation and consumables to the medical, research ... , Chairman and Chief Executive Officer, will present at ... 10, 2014 at 10:20 a.m. ET. The conference will ... New York City . ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... Reportlinker.com announces that a new market research report ... European Markets for Interventional Cardiology Devices 2011 ... In 2010, the European markets ... euro1.5 billion. In 2010, the fastest growing European ...
... MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- ... today announced the publication of results from the Phase ... in the peer-reviewed journal ,Headache., The manuscript, titled MAP0004, ... Acute Treatment of Migraine, has been posted online and ...
Cached Medicine Technology:Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 2Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 3Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 4Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 5Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 6Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 7Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 8Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 9Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 10Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 11Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 12Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 13Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 14Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 15Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 16Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 17Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 18Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 19Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 20Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 21Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 2Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 3Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 4
(Date:9/2/2014)... 2014 Cancer screening is a critical approach for ... more treatable. But while there are already existing ways ... a great need for even more safe, cheap and ... a team of researchers led by Shaoxin Li at ... of a new, non-invasive method to screen for prostate ...
(Date:9/2/2014)... Warwick, R.I. (PRWEB) September 02, 2014 As ... analyze shifts in an industry and predict change. Fortunately for ... years, enabling him to identify markets that are eager for ... “My knowledge of the hearing aid market indicated it was ... to the consumer,” Sapio explained. As a result, he took ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... CA (PRWEB) September 02, 2014 ... and collaboration, announces partnership with NTT DoCoMo ... business customers. Splashtop Business Lite is included in ... is a remote desktop software that empower users to ... Splashtop has garnered over 18 million users worldwide. ...
(Date:9/2/2014)... 2014 West Hollywood cosmetic dentist ... for Invisalign. This special offer includes a free consultation ... determine their candidacy for the procedure and answer any ... may also be eligible for the Summer Invisalign special, ... the month of August, patients who choose Invisalign will ...
Breaking Medicine News(10 mins):Health News:New method for non-invasive prostate cancer screening 2Health News:David Sapio Launches Zounds Hearing Franchise 2Health News:Many nurses unprepared to meet dying patients 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2
... cheap, ruggedized forensics cameras will survive., , , ... , , ... , , , ... , , , , Lights, Camera, Ka-Boom! ...
... Makes Expo SplashPLEASANT GROVE, Utah, March 9 What,s ... Myo-Med ( www.myomed.com ), names like Tom Brady, LaDainian ... to truly helping people. Endorsements by professional athletes of ... these athletes actually used the product for a couple ...
... Stars at the Bal Harbour Shops Raised More Than ... - Seal and The Pointer Sisters Performed to a ... CollectionTommy Lee Jones, Gloria & Emilio Estefan, Anna Kournikova, ... Pat Riley Among the Stars in AttendanceMIAMI, March 9 ...
... Services, Inc. (NYSE: WST ) today announced that ... and William Federici, Chief Financial Officer, will be presenting at ... March 11, 2009 in Miami Beach. A copy of the ... of the Company,s website at www.westpharma.com and the ...
... following is a statement by Reverend Dr. Carlton ... for Reproductive Choice (RCRC) congratulates President Obama for ... funding of human embryonic stem cell research. This ... respects diverse religious and moral views and a ...
... 9 Speaker Nancy Pelosi issued the following ... lifting the Bush Administration,s restrictions on federally financed human ... on federal funding for stem cell research, President Obama ... family in America is just one diagnosis, one phone ...
Cached Medicine News:Health News:Ka-Boom!!! 2Health News:Ka-Boom!!! 3Health News:Ka-Boom!!! 4Health News:Tom Brady Endorsed Pain Cream Returns to Natural Products Expo 2Health News:Destination Fashion 2009 Presented by Stewart Rahr - 2Health News:Destination Fashion 2009 Presented by Stewart Rahr - 3Health News:Religious Coalition for Reproductive Choice President Applauds Obama Stem Cell Policy 2
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Plasma Reagin card test ... and quantitative determination of ... plasma. Uses carbon particle ... reagin. Kits include 10-well ...
Medicine Products: